Gensight Biologics S.a annual current ratio
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Current Ratio Growth & History (SIGHT)
Gensight Biologics S.a's current ratio was 0.39 for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.39 | 0.16 | +66.47% |
| 2024 | 2024-12-31 | 0.24 | −0.02 | −8.50% |
| 2023 | 2023-12-31 | 0.26 | −1.31 | −83.53% |
| 2022 | 2022-12-31 | 1.57 | −0.83 | −34.68% |
| 2021 | 2021-12-31 | 2.40 | −0.16 | −6.12% |
| 2020 | 2020-12-31 | 2.56 | — | — |
Gensight Biologics S.a quarterly current ratio
Q4.24
Q4.25
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.39 | 0.16 | +66.47% |
| Q4 2024 | 2024-12-31 | 0.24 | — | — |
Gensight Biologics S.a current ratio trends
Over the last five fiscal years, Gensight Biologics S.a's current ratio decreased from 2.56 to 0.39, a change of −2.16. The latest reported quarter, Q4 2025, shows 0.39.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as reported current assets divided by reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...